** Shares of drug developer CervoMed fall 71.3% to $2.90 premarket
** Co says its drug, neflamapimod, did not meet the main and secondary goals in a mid-stage trial testing it as a treatment for dementia with Lewy bodies $(DLB)$
** DLB is a form of dementia caused by the accumulation of protein deposits called Lewy bodies in the brain's nerve cells
** CRVO says the drug, neflamapimod, did not achieve the trial's main goal of significantly reducing symptoms of dementia
** CervoMed CEO John Alam says the company is pausing all preparations for its previously planned late-stage trial for the treatment until full analysis of the trial data is complete
** Up to last close, stock up 34.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。